Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, Japan.
Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Medicine (Baltimore). 2022 Feb 11;101(6):e28863. doi: 10.1097/MD.0000000000028863.
In addition to advanced non-small cell lung cancer, nanoparticle albumin-bound paclitaxel (nab-PTX) may also harbor potential benefit for patients with relapsed small cell lung cancer (SCLC), since weekly paclitaxel (PTX) shows modest activity for relapsed SCLC. We evaluated the efficacy and safety of both weekly nab-PTX and PTX for relapsed SCLC.We retrospectively reviewed 52 consecutive relapsed SCLC patients who were treated with weekly nab-PTX or PTX at our hospital.The response rate, median progression-free survival and overall survival with nab-PTX and PTX were 5.6 vs 8.8%, 3.2 vs 1.7 months, and 5.4 vs 4.5 months, respectively. No statistically significant differences were observed. There was no statistical difference between the 2 groups for ≥Grade 3 adverse events.Weekly nab-PTX and PTX showed similar activity for relapsed SCLC. The toxicity profile of nab-PTX was equally tolerable to that of PTX.
除了晚期非小细胞肺癌，白蛋白结合紫杉醇纳米粒（nab-PTX）对于复发性小细胞肺癌（SCLC）患者也可能具有潜在益处，因为每周紫杉醇（PTX）对复发性 SCLC 具有适度的活性。我们评估了每周 nab-PTX 和 PTX 治疗复发性 SCLC 的疗效和安全性。我们回顾性分析了在我院接受每周 nab-PTX 或 PTX 治疗的 52 例连续复发性 SCLC 患者。nab-PTX 和 PTX 的缓解率、中位无进展生存期和总生存期分别为 5.6% vs 8.8%、3.2 个月 vs 1.7 个月和 5.4 个月 vs 4.5 个月。没有观察到统计学上的显著差异。两组之间≥3 级不良事件发生率无统计学差异。每周 nab-PTX 和 PTX 对复发性 SCLC 的活性相似。nab-PTX 的毒性谱与 PTX 同样耐受。
